18 research outputs found

    HYDROGEN EMBRITTLEMENT IN Al-Li-Cu-Mg ALLOYS (8090-T651)

    No full text
    This paper describes the hydrogen embrittlement (HE) of an Al-Li alloy aged at 190°C and with different durations of ageing (10, 15, 20 and 30 hr). Two techniques were employed to measure HE : a) cathodic polarization in a molten salts bath with -3 V/Ag on tensile specimens ; b) gaseous hydrogenation on disks. Hydrogen charging was achieved at 190°C. The results show that HE is important when the alloy is in the over-aged condition

    A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome.

    Get PDF
    Contains fulltext : 156874.pdf (publisher's version ) (Open Access)Calcium channel blockers (CCBs) are prescribed to patients with Marfan syndrome for prophylaxis against aortic aneurysm progression, despite limited evidence for their efficacy and safety in the disorder. Unexpectedly, Marfan mice treated with CCBs show accelerated aneurysm expansion, rupture, and premature lethality. This effect is both extracellular signal-regulated kinase (ERK1/2) dependent and angiotensin-II type 1 receptor (AT1R) dependent. We have identified protein kinase C beta (PKCbeta) as a critical mediator of this pathway and demonstrate that the PKCbeta inhibitor enzastaurin, and the clinically available anti-hypertensive agent hydralazine, both normalize aortic growth in Marfan mice, in association with reduced PKCbeta and ERK1/2 activation. Furthermore, patients with Marfan syndrome and other forms of inherited thoracic aortic aneurysm taking CCBs display increased risk of aortic dissection and need for aortic surgery, compared to patients on other antihypertensive agents

    Study of the reaction stages and kinetics of the europium oxide carbochlorination

    Get PDF
    The europium oxide (Eu2O3(s)) chlorination reaction with sucrose carbon was studied by thermogravimetry between room temperature and 1223 K (950 °C). The nonisothermal thermogravimetry showed that the reaction consists of three stages, and their stoichiometries were studied. The product of the first stage was europium oxychloride, and it showed independence of the reaction kinetics with the carbon content. Subsequently, in the second stage, the EuOCl(s) was carbochlorinated with formation of EuCl3(l) and its evaporation is observed in the third stage. The analysis by Fourier transform infrared spectroscopy of gaseous species showed that the reaction at second stage occurs with the formation of CO2(g) and CO(g). Both reactants and products were analyzed by X-ray diffraction, scanning electron microscopy and wavelength-dispersive X-ray fluorescence spectroscopy. The influence of carbon content, total flow rate, sample initial mass, chlorine partial pressure, and temperature were evaluated. The second stage kinetics was analyzed, which showed an anomalous behavior caused by generation of chlorine radicals during interaction of Cl2(g) and carbon. It was found that the reaction rate at 933 K (660 °C) was proportional to a potential function of the chlorine partial pressure whose exponent is 0.56. The conversion curves were analyzed with the Avrami-Erofeev model and it was obtained an activation energy of 154 ± 5 kJ mol–1.Fil: Pomiro, Federico José. Comisión Nacional de Energía Atómica. Gerencia Complejo Tecnológico Pilcaniyeu; Argentina. Comisión Nacional de Energía Atómica. Centro Atómico Bariloche; ArgentinaFil: Fouga, Gastón Galo. Comisión Nacional de Energía Atómica. Gerencia Complejo Tecnológico Pilcaniyeu; Argentina. Comisión Nacional de Energía Atómica. Centro Atómico Bariloche; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Patagonia Norte; ArgentinaFil: Gaviría, Juan Pablo. Comisión Nacional de Energía Atómica. Gerencia Complejo Tecnológico Pilcaniyeu; Argentina. Comisión Nacional de Energía Atómica. Centro Atómico Bariloche; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Patagonia Norte; ArgentinaFil: Bohe, Ana Ester. Universidad Nacional del Comahue. Centro Regional Universitario Bariloche; Argentina. Comisión Nacional de Energía Atómica. Gerencia Complejo Tecnológico Pilcaniyeu; Argentina. Comisión Nacional de Energía Atómica. Centro Atómico Bariloche; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Patagonia Norte; Argentin

    Relation of uric acid levels to aortic root dilatation in hypertensive patients with and without metabolic syndrome*

    No full text
    Objective: Uric acid (UA) is considered to be a powerful predictor of cardiovascular risk and hyperuricemia might be involved in the metabolic syndrome (MS). This study aims to investigate the relation between UA levels and aortic root dilatation. Methods: A total of 348 hypertensive patients [age (67.5±9.8) years] with or without MS were included in the study. The aortic root diameters at the aortic annulus, the sinuses of Valsalva, the sinotubular junction, and the proximal part of the ascending aorta were measured using a two-dimensional (2D) echocardiography. Serum UA levels were also measured for all patients. Results: A high UA level is independently associated with aortic root diameters at the sinuses of Valsalva (P=0.001) and the proximal ascending aorta (P<0.0001) in the hypertensive patients without MS. In contrast, aortic root diameters were not significantly related to UA levels in the hypertensive patients with MS. Furthermore, increased UA levels were associated with an increased risk for aortic root dilatation in the patients without MS (sex-adjusted hazard ratio 1.75, 95% confidence intervals (CI) 1.27–2.41), but not in those with MS. Conclusions: This study demonstrated an independent relationship between the aortic root dimensions and increased levels of serum UA in the hypertensive patients without MS. Further understanding of the mechanisms underlying these associations may allow a clearer interpretation of the potential value of specific urate-lowering treatment on cardiovascular disease
    corecore